Novel hydroxypropyl-β-cyclodextrin and method for producing same
An aqueous-based process optimizes HPβCD production to achieve low MS and β-CD content, addressing solvent residue issues and enhancing pharmaceutical safety and efficacy.
Patent Information
- Application Number
- JP2020573107
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-08
- Filing Date
- 2019-06-28
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-06-28
AI Technical Summary
Existing methods for producing hydroxypropyl-β-cyclodextrin (HPβCD) struggle to achieve a molar degree of substitution (MS) of 0.71 or less while maintaining a low content of residual β-cyclodextrin (β-CD) and minimizing organic solvent residues, which are critical for pharmaceutical applications, especially for intrathecal administration.
A novel aqueous-based hydroxypropylation process is developed, optimizing parameters such as temperature, propylene oxide ratio, and addition rate to produce HPβCD with an MS of 0.71 or less and a β-CD content of 0.3% or less, without using organic solvents during purification.
The process results in HPβCD with improved safety and efficacy for pharmaceutical use, enhancing the stabilization of active pharmaceutical ingredients and reducing the risk of solvent toxicity, suitable for intrathecal administration.
Smart Images

Figure 0007581055000007 
Figure 0007581055000008 
Figure 0007581055000009
Abstract
Description
[Technical field]
[0001] The present invention relates to a novel hydroxypropyl-β-cyclodextrin (HPβCD) and to a novel process useful for its preparation. The present invention also relates to the use of this HPβCD as an excipient. The present invention also relates to HPβCD for use as a medicament, more particularly for the treatment or prevention of diseases or conditions associated with cholesterol overload and / or storage and / or accumulation in tissues and thus their consequences, for example certain disorders of the central nervous system or cardiovascular system. [Background technology]
[0002] Cyclodextrins are cyclic oligosaccharides derived from the enzymatic degradation of starch. The three most common natural cyclodextrins are composed of 6, 7 or 8 α-D-glucopyranose units in a chair-like arrangement linked together by α-1,4 bonds. They are more commonly referred to as α, β or γ-cyclodextrin, respectively. Their tertiary structural appearance is in the form of a truncated cone, with the exterior being the hydroxyl groups that represent the highly hydrophilic portion of the cyclodextrin. The interior or cavity of the cyclodextrin cone is composed of hydrogen atoms from the C3 and C5 carbons and additional oxygen atoms involved in glycosidic bonds, resulting in its non-polar nature.
[0003] Cyclodextrins, which have a hydrophilic outer part and a hydrophobic cavity, are commonly used due to their ability to encapsulate lipophilic compounds or groups and thus their role in protectors and solubilizers of these lipophilic compounds or compounds with lipophilic groups. Therefore, they are usually found in the field of food processing as well as in galenics, where they are used as excipients in pharmaceutical preparations.
[0004] Each anhydroglucose unit of cyclodextrin contains three reactive hydroxyl groups, originating from the C2, C3 and C6 carbons, and therefore a great number of derivatives have already been synthesized by grafting different groups onto these hydroxyl groups, among which hydroxypropylcyclodextrin, methylcyclodextrin and sulfoalkylcyclodextrin may be mentioned.
[0005] In particular, hydroxypropyl-β-cyclodextrin (HPβCD) is widely used in galenism for the oral or parenteral delivery of active ingredients.
[0006] Usually, HPβCD is obtained by reacting β-cyclodextrin with propylene oxide in a basic medium, after which the reaction is neutralized by adding hydrochloric acid.
[0007] The crude reaction product is then purified from impurities, typically: - Reagents, e.g. residual (unsubstituted) β-cyclodextrin; - reaction by-products such as salts, propylene glycol (propane-1,2-diol), dipropylene glycol; - Decomposition products of β-cyclodextrin or its linear structure; - Microbiological products such as endotoxins It is refined to reduce
[0008] This purification involves filtration, bleaching, demineralization, washing with ethanol, and extraction with acetone. The purification may be carried out using one or more treatments such as dialysis.
[0009] From a regulatory standpoint, the degree of purification required is high, especially if HPβCD is intended for the pharmaceutical market. These regulatory requirements are further increased if the route of administration is invasive.
[0010] In particular, it is known that HPβCD has favorable effects on certain diseases of the central nervous system (CNS), such as certain incurable diseases, such as Niemann-Pick disease type C. In these pathological conditions, the intrathecal route is preferred and the safety requirements are very high.
[0011] Thus, preferably, HPβCD should have an average molar degree of substitution (MS) at most equal to 0.71, preferably in the range of 0.50 to 0.71, and contain as few impurities as possible, among which residual β-cyclodextrin (β-CD) has been identified as one that may exhibit toxic properties.
[0012] A notable technical difficulty lies in matching this MS range with a low content of residual β-CD. Naturally, this MS range is particularly low. Preparation of HPβCD with a low MS usually means that less hydroxypropylating reagent is used. It then follows that the reaction product contains more unreacted β-CD, i.e., residual β-CD.
[0013] However, this β-CD is difficult to remove, but if its content is sufficiently reduced, this leads to an increase in MS, since the latter is determined based on all cyclodextrin molecules containing unsubstituted β-CD.
[0014] In addition, after hydroxypropylation, it is also necessary to reduce the reaction by-products, such as propylene glycol or dipropylene glycol. This in turn leads to an increase in the proportion of β-CD, since the total dry mass of HPβCD is reduced by the removal of these other by-products. After hydroxypropylation, the propylene glycol content, for example, is of course typically equal to at least 5.0% by dry weight.
[0015] It is therefore difficult to produce HPβCD with a given MS and a given β-CD content, especially considering that this MS must be at most equal to 0.71 and the β-CD content must be as low as possible, and this difficulty increases if it is also desired to minimize by-products such as propylene glycol and dipropylene glycol.
[0016] In the application WO 2016 / 201137 (VTESSE), various methods are proposed to purify HPβCD, including complexation with organic compounds, precipitation, adsorption chromatography on alumina. In this patent application, it was possible to obtain HPβCD with a reduced β-CD content and an MS of less than 0.71. However, all purification processes make it possible to obtain the organic solvent used, e.g. acetone or methanol.
[0017] The use of these organic solvents is particularly restricted and, to the extent that they are used, requires strict supervision, particularly to ensure the safety of the handlers. Moreover, these solvents are found as impurities in the final product and represent a toxicological risk to the consumer.
[0018] As a result thereof, there is an unmet need to provide an HPβCD with improved safety, in particular with a low MS of 0.71 or less, and especially when the latter is intended to be injected, for example, intravenously or intrathecally. Summary of the Invention [Problem to be solved by the invention]
[0019] One object of the present invention is to provide HPβCD with improved qualities, especially for use as an excipient or active pharmaceutical ingredient.
[0020] Another object of the present invention is to provide HPβCD which is particularly effective for solubilizing or stabilizing active agents, especially active pharmaceutical ingredients.
[0021] Another object of the present invention is to provide a HPβCD having a reduced content of residual β-CD, which, in contrast to what is the case in the prior art, may be free of undesirable organic solvents such as methanol, ethanol, acetone, acetonitrile and chloroform, and having an MS at most equal to 0.71. [Means for solving the problem]
[0022] The Applicant has achieved this after extensive testing which has resulted in the development of a HPβCD having an MS at most equal to 0.71 and a β-CD content at most 0.3% (dry / dry), preferably less than or equal to 0.2% (dry / dry).
[0023] Furthermore, the HPβCD according to the invention may have remarkable application properties, especially with regard to the stabilization of pharma- ceutical active proteins.
[0024] This HPβCD, unlike the HPβCD used in patent application WO 2016 / 201137, may advantageously be free of organic solvents that typically result from the HPβCD purification process.
[0025] In fact, the HPβCD of the invention may advantageously be obtained by a novel process carried out in an aqueous medium. In the novel process, solution is more present in the hydroxypropylation step than in the purification step. In particular, the applicant has shown that a judicious choice of the hydroxypropylation parameters makes it possible to obtain the HPβCD of the invention.
[0026] It is therefore possible to formulate with a purification step involving undesired organic solvents, which are inevitably found in the final product. A purification step carried out in an aqueous medium is sufficient. The HPβCD thus obtained has an MS of 0.71 or less, in particular in the range of 0.50 to 0.71. Its β-CD content is reduced, being 0.3% or less, preferably 0.2% or less. Undesired reaction by-products such as propylene glycol and dipropylene glycol may also be reduced.
[0027] The first subject of the invention is therefore - having an average molar substitution (MS) of 0.71 or less; and characterised in that it has a β-cyclodextrin (β-CD) content of less than or equal to 0.3% by dry weight, preferably less than or equal to 0.2%; Hydroxypropyl-β-cyclodextrin (HPβCD).
[0028] Another subject of the invention is (a) preparing an aqueous solution comprising β-cyclodextrin (β-CD) and sodium hydroxide, wherein the amount of sodium hydroxide used is less than 3.7% by dry weight of sodium hydroxide relative to the dry weight of β-CD; In step (b) of adding propylene oxide to the solution obtained in step (a), - the temperature of the solution obtained in step (a) before the introduction of propylene oxide is selected in the range of 80°C to 120°C; - the molar ratio of propylene oxide / anhydroglucose used is selected within the range of 0.70 / 1.00 to 0.86 / 1.00; - the rate of addition of propylene oxide is selected within the range of 0.15-0.30 kg / h / kg of β-CD; and step (b) characterized in: a purification step (c), characterized in that no organic solvent is used; (d) recovering the HPβCD thus obtained; The present invention relates to a method for preparing HPβCD, which is particularly useful for preparing the HPβCD of the present invention, comprising:
[0029] Another subject of the invention is HPβCD obtainable by the process for preparing HPβCD according to the invention.
[0030] The invention also relates to the use of glycerol as a drug and / or excipient, and / or to encapsulate a substance, and / or to solubilize a substance in an aqueous medium, and / or to improve the chemical stability of a substance, and / or to improve the delivery of a substance to and through biological membranes, and / or to enhance the physical stability of a substance, and / or to blend a substance from a liquid form to a powder form, and / or to prevent the interaction of one substance with another, and / or to reduce local irritation following topical or oral administration of a substance, and / or to prevent absorption of a substance in certain tissues such as the skin, and / or to obtain a sustained release of a substance, and / or to mask the taste of a substance, in particular its bitter taste, and / or to mask the odour of a substance, and / or to increase the bioavailability of a substance. improvement The present invention also relates to the use of HPβCD for the treatment of cancer. [Brief description of the drawings]
[0031] [Figure 1] The monograph of Hydroxypropyl Betadex (HPβCD) from USP41 NF36 is presented and is an integral part of the description of the patent application. [Diagram 2] The monograph of Hydroxypropyl Betadex (HPβCD) from USP41 NF36 is presented and is an integral part of the description of the patent application. [Diagram 3] The monograph of Hydroxypropyl Betadex (HPβCD) from USP41 NF36 is presented and is an integral part of the description of the patent application. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] The present invention therefore relates to a hydroxypropyl-β-cyclodextrin (HPβCD) characterized in that it has an average molar degree of substitution (MS) of less than or equal to 0.71 and a β-cyclodextrin (β-CD) content of less than or equal to 0.3% by dry weight.
[0033] It is generally understood that the expression "HPβCD" generally encompasses a mixture of HPβCD molecules as well as the material resulting from the process for their preparation. Indeed, as opposed to a chemical compound having a clearly defined structure, HPβCD generally corresponds to a mixture of HPβCD molecules having different substitution profiles and patterns, and therefore structurally distinct.
[0034] Firstly, the HPβCD of the present invention is characterized by its average molar substitution (MS) of less than or equal to 0.71. Preferably, this MS is selected in the range of 0.50 to 0.71. It is more preferably less than or equal to 0.70, preferably less than or equal to 0.69. Preferably, this MS is at least equal to 0.58, i.e. selected in the range of 0.58 to 0.71. Furthermore, this MS is generally at least equal to 0.60, even at least equal to 0.65. It is typically equal to 0.66, or equal to 0.67, or equal to 0.68, or equal to 0.69.
[0035] It is recalled here that the "average molar substitution (MS)" corresponds to the average number of hydroxypropyl groups per anhydroglucose unit. It should be noted that the MS is different from the average molecular substitution (DS), which corresponds to the average number of hydroxypropyl groups per cyclodextrin molecule and is therefore a function of the number of anhydroglucose units that make up the starting cyclodextrin. Thus, in the case of HPβCD, the DS is equal to 7 times the MS, since the β-cyclodextrin consists of 7 anhydroglucose units.
[0036] MS can usually be determined by one skilled in the art by proton nuclear magnetic resonance (NMR), preferably according to the "Hydroxypropylbetadex; molar substitution" method of USP41 NF36, reproduced in the appendix.
[0037] As mentioned above, this mixture will usually contain residual native β-cyclodextrin (β-CD) molecules, i.e., molecules that are not hydroxypropylated but which are advantageously reduced in the HPβCD of the present invention.
[0038] Thus, HPβCD of the present invention has a β-CD content of 0.3% or less, preferably 0.2% or less, preferably 0.1% or less, this percentage being expressed as the dry weight of β-CD relative to the total dry weight of HPβCD.
[0039] This residual β-CD content can usually be determined by a person skilled in the art by high performance liquid chromatography (HPLC), preferably according to the procedure according to the method of USP41 NF36 ("Limits for Hydroxypropyl Betadex; Betadex, Propylene Glycol, and Other Related Substances") reproduced in the appendix.
[0040] Preferably, the substitution pattern of the HPβCD according to the invention is as follows: The percentage of unsubstituted (no-OHP) moieties is: at least equal to 25.0%, preferably 30.0%, preferably 35.0%, preferably 40.0%; and / or at most equal to 55.0%, preferably 52.0%, preferably 50.0%, preferably 49.0%, preferably 48.0%; and / or The percentage of C2 substituted (2OHP) moieties is: at least equal to 15.0%, preferably 20.0%, preferably 24.0%, preferably 25.0%, preferably 26.0%, preferably 27.0%, preferably 28.0%, preferably 28.5%; and / or at most equal to 35.0%, preferably 31.0%, preferably 30.5%; and / or The percentage of C3 substituted (3OHP) moieties is: at least equal to 5.0%, preferably 6.0%, more preferably 7.0%; and / or at most equal to 10.0%, preferably 9.0%, preferably 8.0%; and / or The percentage of C6 substituted (OHP) moieties is: - at least equal to 1.0% or even 2.0%; and / or at most equal to 10.0%, preferably 7.0%, preferably 6.0%, preferably 5.0%, preferably 4.0%; and / or The proportion of C2 and C3 substituted (2,3-di-OHP) moieties is: at least equal to 5.0%, preferably 8.0%, preferably 9.0%; and / or at most equal to 25.0%, preferably 20.0%, preferably 15.0%, preferably 12.0%, preferably 11.0%, preferably 10.0%; and / or The proportion of C2 and C6 substituted (2,6-di-OHP) moieties is: at least equal to 1.0%, preferably equal to 2.0%; and / or at most equal to 10.0%, preferably 6.0%, preferably 5.0%, preferably 4.0%; and / or The proportion of two C3 substituted (3,3'-di-OHP) moieties is: at least equal to 0.2%, preferably 0.3%, more preferably 0.5%; and / or at most equal to 2.0%, preferably 1.5%, preferably 1.0%, preferably 0.8%; and / or The proportions of C2, C3 and C6 substituted (2,3,6-tri-OHP) moieties are: at least equal to 0.5%, preferably 0.6%, preferably 0.7%, preferably 0.8%; and / or at most equal to 4.0%, preferably 3.0%, more preferably 2.0%, preferably 1.5%, preferably 0.8%.
[0041] These percentages correspond to the percentage of anhydroglucose units having the type of substitution considered. For example, for a 2OHP value equal to 30.0%, it is estimated that 30.0 mole % of the anhydroglucose units of HPβCD are substituted by a hydroxypropyl group at the C2 carbon. As a further example, for a 3,3'-di-OHP value equal to 0.4%, it is estimated that 0.4 mole % of the anhydroglucose units of HPβCD are substituted twice at the C3 carbon (i.e., the C3 carbon has two hydroxypropyl groups). As a final example, for a 2,6-di-OHP value equal to 5.0%, it is estimated that 5.0 mole % of the anhydroglucose units of HPβCD are substituted by a hydroxypropyl group at both the C2 and C6 carbons. In the first example, reference will be made to monosubstitution, while in the last two examples, reference will be made to disubstitution.
[0042] Preferably, the HPβCD according to the invention comprises less than 5.0%, preferably less than 4.0%, preferably less than 3.0%, preferably less than 2.0%, preferably less than 1.0%, preferably less than 0.5% of substitutions other than those listed above, such as for example 3,6-OHP substitutions. More preferably, the HPβCD according to the invention does not comprise other types of substitutions than those listed above. The expression "free of other types of substitutions" is understood to mean that anhydroglucose units containing such substitutions cannot be detected, in particular by the "box-keeper" method, which method comprises subjecting the HPβCD to the following successive steps: permethylation, hydrolysis, reduction, peracetylation.
[0043] Preferably, the HPβCD substitution pattern according to the invention is as follows: The percentage of substitutions corresponding to one substitution is: at least equal to 60%, preferably 70%, preferably 73%, and / or o at most equal to 80%, or even 78%, or even 77%, or even 78%; and / or The percentage of substitutions corresponding to two substitutions is: at least equal to 15%, or even 20%, or even 22%, or even 23%; and / or o at most equal to 40%, preferably 35%, preferably 30%, preferably 28%, preferably 26%, preferably 25%; and / or The percentage of substitutions corresponding to three substitutions is: at least equal to 1% or even 2%; and / or o at most equal to 5%, preferably 4%, preferably 3% or even 2%; and / or The C2 / C6 substitution ratio is: o at least equal to 2.0, preferably 3.0, preferably 4.0, preferably 5.0; and / or o up to equal to 10.0, or even 8.0, or even 7.5; and / or The C2 / C3 substitution ratio is: at least equal to 1.5, preferably 2.0, preferably 2.1, preferably 2.2; and / or o At maximum, it is equal to 3.0 or even 2.5.
[0044] These substitution patterns can be determined by one skilled in the art, for example, following a method similar to the "Hakomori" method, typically by subjecting HPβCD to the following successive steps: permethylation, hydrolysis, reduction, peracetylation.
[0045] For example, it is possible to follow the method as described in U.S. Pat. No. 5,096,893, which is incorporated by reference, including columns 6, Examples 9 to 7, Examples 10. Typically, the method described in U.S. Pat. No. 5,096,893 is as follows: Sodium hydride (0.07 mol) is added to anhydrous dimethylsulfoxide (20 ml) under argon and the mixture is heated at about 60° C. for 1 hour. Then, HPβCD (4 g), dried (110° C. for 3 hours) and dissolved in dimethylsulfoxide (15 ml), is added and left under argon with stirring at room temperature for 3 hours. The reaction medium is cooled in an ice bath and methyl iodide (10 ml, 0.161 mol) is added dropwise. After a further hour in the ice bath, the mixture is left overnight with stirring. Then, water (24 ml) is added with cooling, while the product is extracted twice with chloroform (total of 90 ml). The extract is washed with water (20 ml) and evaporated. The residue is treated with water (25 ml) and extracted three times with ether (total of 75 ml). The extract is washed with water and then evaporated. The residue is dissolved in ether (100 ml), then stirred in the presence of neutral alumina for 30 min, filtered, then evaporated until typically 3.7 g of permethylated product is obtained. 3 mg of the permethylated product is dissolved in aqueous trifluoroacetic acid (0.5 ml), then stored overnight at 100° C. in a screw-cap tube, and concentrated by rinsing with air. The residue and sodium borohydride (100 mg) are dissolved in aqueous ammonia (0.5 ml) and the solution is left at room temperature for 1 h. The solution is acidified with 50% acetic acid (2 drops) and then concentrated. Boric acid is evaporated by co-distillation first with an acetic acid / methanol mixture (1:9, 5 ml) and then with methanol (25 ml). The residue is treated with acetic anhydride and pyridine (2:1, 0.5 ml) for 30 min at 100° C., concentrated, and partitioned between chloroform and water (2:1, 6 ml). The chloroform phase is concentrated and the residue is analyzed by gas chromatography and gas-liquid chromatography coupled to mass spectrometry (GLC-MS). Gas-liquid chromatography is carried out, for example, on a Hewlett Packard 5830A instrument equipped with a flame ionization detector using hydrogen as the carrier gas. Gas-liquid chromatography coupled to mass spectrometry is carried out, for example, on a Hewlett Packard 5790-5970 system using helium as the carrier gas.For example, a Hewlett Packard Ultra 2 type (5% cross-linked methylphenyl silicone) fused glass capillary column (25 m length, 0.20 mm internal diameter) is used. The temperature is programmed as follows: 185° C. for 8 min, 5° C. / min to 250° C., 250° C. for 10 min.
[0046] The inventors have found that when HPβCD has specific substitution patterns, the performance of HPβCD is enhanced. More specifically, the inventors have shown improved stabilization of proteins, particularly proteins of therapeutic interest (hormones, antibodies, etc.).
[0047] Preferably, the HPβCD according to the invention has an organic solvent content of: - d-limonene at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; - ethanol at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; - methanol at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; - acetonitrile at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; - acetone at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; - chloroform at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; These contents are expressed as the dry weight of said organic solvent relative to the total dry weight of HPβCD.
[0048] These organic solvent contents can be determined by the skilled artisan, usually by gas chromatography with mass spectrometric detection (GC / MS), preferably by headspace GC / MS analysis, for example by following the method as described in section A of the Examples.
[0049] Most preferably, the HPβCD according to the invention does not contain detectable amounts of d-limonene, and / or ethanol, and / or methanol, and / or acetonitrile, and / or acetone, and / or chloroform.
[0050] Preferably, the HPβCD according to the invention also has an organic solvent content of: p-xylene at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; and / or toluene at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; and / or l-menthol at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm; and / or - trichloroethylene at less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm, preferably less than 5 ppm, preferably less than 1 ppm; has.
[0051] Most preferably, the HPβCD of the present invention does not contain detectable amounts of p-xylene, and / or toluene, and / or l-menthol, and / or trichloroethylene.
[0052] Preferably, the HPβCD of the present invention is less than 2000 ppm, preferably less than 1000 ppm. pm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm, <467> The total content of Class 1 organic solvents in accordance with the "Residual Solvents" section.
[0053] Preferably, the HPβCD according to the present invention has a concentration of less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm, according to the "General Chapter of USP41 NF36". <467> The total content of class 2 organic solvents in accordance with the "Residual Solvents" section.
[0054] Preferably, the HPβCD according to the present invention has a concentration of less than 2000 ppm, preferably less than 1000 ppm, preferably less than 500 ppm, preferably less than 200 ppm, preferably less than 100 ppm, preferably less than 50 ppm, preferably less than 10 ppm, according to the "General Chapter of USP41 NF36". <467> Residual Solvents" section.
[0055] Alternatively, or in addition to characterization by its content of organic solvents, HPβCD may be defined by the fact that it is available or obtained by a process of hydroxypropylation and purification that excludes the use of organic solvents, i.e., that is carried out entirely in aqueous medium.
[0056] Preferably, the HPβCD according to the invention has the following substitution profile as determined by electrospray ionization-mass spectrometry (ESI-MS): - the signal corresponding to unsubstituted β-CD (HP0): equal to 0.0%; and / or - a signal corresponding to a HPβCD molecule with a degree of substitution equal to 1 (HP1): less than or equal to 3%, preferably less than or equal to 1%, preferably equal to 0%; and / or - a signal corresponding to an HPβCD molecule with a degree of substitution equal to 2 (HP2): less than or equal to 5%, preferably in the range of 0-4%, preferably 1-3%, and / or - a signal corresponding to an HPβCD molecule with a degree of substitution equal to 3 (HP3): in the range of 1 to 10%, preferably 2 to 8%, preferably 3 to 7%; and / or - a signal corresponding to an HPβCD molecule with a degree of substitution equal to 4 (HP4): in the range of 5 to 20%, preferably 7 to 17%, preferably 9 to 15%; and / or - a signal corresponding to an HPβCD molecule with a degree of substitution equal to 5 (HP5): in the range of 10-30%, preferably 15-25%, preferably 17-25%; and / or a signal corresponding to a HPβCD molecule having a degree of substitution equal to −6 (HP6): in the range of 15 to 35%, preferably 20 to 30%, preferably 24.0 to 28.0%; and / or a signal corresponding to a HPβCD molecule having a degree of substitution equal to −7 (HP7): in the range of 10 to 30%, preferably 15 to 25%, preferably 17 to 25%; and / or - a signal corresponding to a HPβCD molecule with a degree of substitution equal to 8 (HP8): in the range of 5 to 20%, preferably 5 to 15%, preferably 6 to 13%; and / or - a signal corresponding to a HPβCD molecule with a degree of substitution equal to 9 (HP9): within the range of 1 to 10%, preferably 2 to 8%, preferably 2 to 6%; and / or - signals corresponding to HPβCD molecules with a degree of substitution equal to 10 (HP10): less than 5%, preferably less than 2%, preferably less than 1%, preferably equal to 1%; and / or - signals corresponding to HPβCD molecules with a degree of substitution equal to or greater than 11 (HP≧11): less than 2%, preferably less than 1%, preferably equal to 0%; and these percentages are expressed relative to the sum of the signals obtained at each degree of substitution, where the signal was greater than the background noise.
[0057] Of course, the term "signal" refers to the area under the curve of the ion corresponding to the degree of substitution of interest. It is accepted that
[0058] In the present specification, the substitution profile is determined by ESI-MS, preferably by averaging measurements carried out in triplicate, and it is possible to follow, in particular, the method described below in Section A of the Examples, in determining this substitution profile.
[0059] Preferably, the HPβCD according to the invention has a propylene glycol content of less than 5.00%, this percentage being expressed as the dry weight of propylene glycol relative to the total dry weight of the HPβCD, preferably less than 2.50%, preferably less than 1.00%, preferably less than 0.50%, preferably less than 0.10%, preferably less than 0.05%.
[0060] This propylene glycol content can usually be determined by a person skilled in the art by high performance liquid chromatography (HPLC) according to the procedure, preferably according to the method of USP41 NF36 ("Monograph of Hydroxypropyl Betadex; Limits of Betadex, Propylene Glycol, and Other Related Substances") reproduced in the appendix.
[0061] Preferably, the HPβCD according to the invention has a dipropylene glycol content of less than or equal to 0.10%, this percentage being expressed as the dry weight of dipropylene glycol relative to the total dry weight of the HPβCD. This dipropylene glycol content is preferably less than or equal to 0.05%, preferably less than or equal to 0.03%. It may, for example, be in the range 0.01-0.05%.
[0062] Preferably, the HPβCD according to the invention has a reducing sugar content of less than 1.0%, this percentage being expressed as the dry weight of reducing sugars relative to the total dry weight of the HPβCD. Preferably, this reducing sugar content is less than 0.5%, preferably less than 0.1%.
[0063] This reducing sugar content can typically be determined by one of skill in the art by the Bertrand method, for example according to the method described in Section A of the Examples below.
[0064] Generally, and advantageously, the HPβCD according to the invention has a chloride content of less than or equal to 1000 ppm, expressed as the dry weight of chloride ions relative to the total dry weight of the HPβCD.Preferably, this chloride content is less than or equal to 500 ppm, preferably less than or equal to 100 ppm, preferably less than or equal to 50 ppm, preferably less than 50 ppm.
[0065] This chloride content can be determined by one skilled in the art, usually by potentiometric titration of a solution of HPβCD with a solution of silver nitrate of known concentration.
[0066] Preferably, the HPβCD according to the invention has a maximum absorbance of 1.00 or less between 230 and 400 nm, said maximum absorbance being measured on a distilled aqueous solution containing 2.50 g (dry) HPβCD per 100 ml of solution using a cell with an optical path length of 10 mm. Preferably, this maximum absorbance is less than 0.50, preferably less than 0.10, preferably less than 0.05, for example in the range of 0.01 to 0.50.
[0067] In an advantageous embodiment, the HPβCD of the invention is in powder form, which advantageously exhibits a mass deficit (or "moisture content") on drying of less than or equal to 10.0%, preferably less than or equal to 5.0%, for example selected from the range 2.0 to 5.0%.
[0068] This water content is usually measured by drying, preferably according to the procedure of the method of USP41 NF36 reproduced in the appendix ("Monograph of Hydroxypropyl Betadex; Defects on Drying"). This can be determined by one skilled in the art by measuring the loss of mass upon drying.
[0069] This powder form is particularly advantageous in the storage and transportation of HPβCD.
[0070] Advantageously, this powdered HPβCD is in the form of an atomized product, ie a powder obtained by spray drying a solution of HPβCD.
[0071] Preferably, the HPβCD according to the invention has a pH in the range of 5.0 to 7.5; said pH is measured on a solution of HPβCD consisting of 2 g of dry HPβCD, 98 g of distilled water and 0.3 ml of a 225 g / L potassium chloride solution.
[0072] Preferably, the HPβCD according to the invention has a conductivity of less than or equal to 200 μS / cm, said conductivity being measured on a distilled water solution containing 10% (dry) HPβCD. Preferably, this conductivity is less than or equal to 100 μS / cm, preferably less than or equal to 50 μS / cm, preferably less than or equal to 25 μS / cm, preferably less than or equal to 10 μS / cm. This conductivity is, for example, in the range of 1 to 10 μS / cm, or even 2 to 5 μS / cm.
[0073] This conductivity can be determined by those skilled in the art, usually following the procedure described in USP41 NF36, reproduced in the appendix ("Monograph of Hydroxypropyl Betadex; Conductivity"). For example, it is possible to follow the method described in Section A of the Examples below.
[0074] Preferably, the HPβCD according to the invention has a content of impurities relative to the HPβCD other than propylene glycol and β-CD of less than 0.5%, preferably less than 0.1%.
[0075] This content of HPβCD impurities other than propylene glycol and β-CD can usually be determined by a person skilled in the art by high performance liquid chromatography (HPLC), preferably according to the procedure according to the method of USP41 NF36 reproduced in the appendix ("Limits for Betadex, Propylene Glycol, and Other Related Substances"), it being understood that the impurities related to HPβCD other than propylene glycol and β-CD correspond to "other related substances" in said method.
[0076] Preferably, the HPβCD of the present invention also complies with the U.S. monograph effective from 1 June 2018. Preferably, the HPβCD of the present invention also complies with the Chinese monograph effective from 1 June 2018. Preferably, the HPβCD of the present invention also complies with the European monograph effective from 1 June 2018.
[0077] Another subject of the invention is (a) preparing an aqueous solution comprising β-cyclodextrin (β-CD) and sodium hydroxide, wherein the amount of sodium hydroxide used is less than 3.7% by dry weight of sodium hydroxide relative to the dry weight of β-CD; In step (b) of adding propylene oxide to the solution obtained in step (a), - the temperature of the solution obtained in step (a) before the introduction of propylene oxide is selected in the range of 80°C to 120°C; - the molar ratio of propylene oxide / anhydroglucose used is selected within the range of 0.70 / 1.00 to 0.86 / 1.00; - the rate of addition of propylene oxide is selected within the range of 0.15-0.30 kg / h / kg of β-CD; and step (b) characterized in: a purification step (c), characterized in that no organic solvent is used; (d) recovering the HPβCD thus obtained; A method for preparing HPβCD, which is particularly useful for preparing HPβCD as described above, comprising:
[0078] Preferably, the dry mass of β-CD in the solution of step (a) is chosen in the range of 30-70% by weight, this percentage being expressed by the dry weight of β-CD relative to the total weight of the solution. Preferably, this dry mass of β-CD is chosen in the range of 40-60%, preferably 45-55%, preferably 50-55%.
[0079] Preferably, the amount of sodium hydroxide in the solution of step (a) is selected in the range of 0.5 to 3.6% by dry weight of sodium hydroxide relative to the dry weight of β-CD. More preferably, this amount of sodium hydroxide is 1.0% or more, preferably 1.2% or more, preferably 1.3% or more, preferably 1.4% or more, preferably 1.5% or more, even 1.6% or more, even 1.7% or more, even 1.8% or more, even 1.9% or more, even 2.0% or more, even 2.1% or more, even 2.2% or more, even 2.3% or more, even 2.4% or more, even 2.5% or more, even 2.6% or more, even 2.7% or more, even 2.8% or more, even 2.9% or more. Preferably, this amount of sodium hydroxide is 3.5% or less, preferably 3.4% or less, preferably 3.3% or less, preferably 3.2% or less, preferably 3.1% or less, preferably 3.0% or less, preferably 2.9% or less.
[0080] Preferably, in step (b), the temperature of the aqueous solution of β-CD before the introduction of propylene oxide is greater than or equal to 85° C., preferably greater than or equal to 90° C. This temperature is also preferably less than or equal to 110° C., preferably less than or equal to 100° C. It is, for example, chosen in the range 90-100° C., preferably 94-96° C. It is, for example, equal to about 95° C.
[0081] Preferably, in step (b), the molar ratio of propylene oxide / anhydroglucose used is greater than or equal to 0.75 / 1.00, preferably greater than or equal to 0.80 / 1.00, preferably greater than or equal to 0.82 / 1.00, preferably greater than or equal to 0.84 / 1.00, preferably equal to 0.85 / 1.00.
[0082] Preferably, in step (b), the addition rate of propylene oxide is selected in the range of 0.20 to 0.30 kg / h / kg of β-CD, preferably 0.20 to 0.25 kg / h / kg of β-CD, preferably 0.21 to 0.23 kg / h / kg of β-CD, for example equal to 0.22 kg / h / kg of β-CD.
[0083] The reaction may then be neutralized, for example, by adding hydrochloric acid.
[0084] To carry out step (c), the HPβCD obtained in step (b) may typically be subjected to one or more treatments selected from filtration, nanofiltration, treatment with activated carbon and demineralization.
[0085] Preferably, this purification is carried out in the following order: (b.1) Decolorization; (b.2)filtration; (b.3) Membrane purification This includes processing performed in
[0086] Preferably, the decolorization step (b.1) is carried out using an activated carbon treatment, typically carried out in batch mode. Preferably, the treatment is carried out at 70°C ± 5°C for at least 1 hour. It will be carried out.
[0087] Preferably, step (b.2) comprises at least one filtration step through a bag filter. Preferably, step (b.2) comprises at least one filtration step through a 0.22 μm cartridge filter. Preferably, step (b.2) comprises at least one filtration step through a 0.1 μm cartridge filter, preferably prior to the filtration optionally carried out with a 0.22 μm cartridge filter.
[0088] Preferably, the membrane purification step (b.3) is carried out by nanofiltration, preferably using a nanofiltration module equipped with a membrane having a cut-off threshold of less than 800 Da or a nominal retention of CaCl2 of more than 65%, at a pressure of less than 35 bar and a temperature of more than 45°C.
[0089] Preferably, the purification further comprises a demineralization step (b.4), advantageously comprising passing through a cation exchange column and then an anion exchange column. Preferably, the demineralization further comprises passing through a mixed bed. Preferably, step (b.4) is carried out such that the resistivity of the product at the outlet is greater than 500,000 Ω·cm.
[0090] Preferably, the processes (b.1) and (b.2) are repeated after membrane purification (b.3) or, optionally, after a demineralization process (b.4).
[0091] Advantageously, especially if it is desired to obtain a powdered HPβCD, the process of the invention comprises, after said purification, a step of drying the hydroxypropylated and optionally purified product, which can be carried out by any technique known to the person skilled in the art, typically by evaporation or by spray drying, preferably by spray drying.
[0092] This spray drying may be single-stage or multi-stage spray drying, in which case the spray dryer is coupled to a fluidized bed, optionally integrated with a spray drying tower, making it possible to agglomerate the particles formed by spray drying. The latter process is particularly advantageous when it is desired to obtain powders with a larger average diameter and depending on the desired flow for the resulting powders.
[0093] The HPβCD of the present invention can be used in a variety of applications, among which a distinction is made here between therapeutic and non-therapeutic applications.
[0094] The present invention therefore firstly relates to an HPβCD according to the invention for use as a medicament.
[0095] Preferably, this use is directed to the treatment or prevention of conditions or diseases associated with cholesterol overload and / or storage and / or accumulation in tissues and their consequences, including, for example, cardiovascular diseases, vascular diseases, occlusive peripheral arterial diseases such as atherosclerosis or complications associated with atheroma, diseases of the central nervous system, such as Alzheimer's disease, Parkinson's disease, focal segmental glomerulosclerosis affecting the central nervous system, and lysosomal diseases, such as Niemann-Pick disease, for example Niemann-Pick type A, Niemann-Pick type B, or Niemann-Pick type C. Complications associated with atheroma that are treated and / or prevented by the use of HPβCD according to the invention are, but are not limited to, ischemia, for example myocardial ischemia, coronary disease, angina pectoris, acute coronary syndromes, myocardial infarction, mesenteric infarction, stroke, aneurysm or arteriopathy of the lower limbs.
[0096] The HPβCD of the present invention is intended for use in the treatment of Niemann-Pick disease type C, or for use in the treatment of focal segmental glomerulosclerosis.
[0097] Preferably, the HPβCD of the invention is intended for administration to humans or animals, preferably humans.
[0098] The HPβCD of the invention can be administered orally, parenterally, dermally or mucosally. Parenteral routes include, for example, subcutaneous, intravenous, intramuscular or intraperitoneal administration, the latter being rather prepared for animals. Mucosal routes include, for example, intranasal administration, pulmonary administration or administration via the rectal mucosa. Dermal routes include, for example, transdermal routes, in particular via transdermal devices, typically patches. In the case of treatment and / or prevention of diseases of the central nervous system, intrathecal or spinal routes may also be used.
[0099] The present invention also relates to the use of an HPβCD according to the invention in the manufacture of a medicament intended in particular for the treatment and / or prevention of the abovementioned conditions and diseases. It also relates to a method for the treatment and / or prevention of the abovementioned conditions and diseases in a subject, comprising the administration of an HPβCD according to the invention in a therapeutically effective amount.
[0100] The HPβCD according to the invention also has other possible applications, in particular selected from the applications usually found in products of this type.
[0101] The invention therefore also relates to the use of saccharides as excipients and / or to encapsulate a substance and / or to solubilize a substance in an aqueous medium and / or to improve the chemical stability of a substance and / or to improve the delivery of a substance to and through biological membranes and / or to enhance the physical stability of a substance and / or to blend a substance from a liquid form to a powder form and / or to prevent the interaction of one substance with another and / or to reduce local irritation following topical or oral administration of a substance and / or to prevent absorption of a substance in certain tissues such as the skin and / or to obtain a sustained release of a substance and / or to mask the taste of a substance, in particular its bitter taste and / or to mask the odour of a substance and / or to increase the bioavailability of a substance. improvement The present invention also relates to the use of HPβCD for the treatment of cancer.
[0102] Preferably, these substances are lipophilic compounds or compounds which have at least one lipophilic group.
[0103] These lipophilic compounds or compounds having at least one lipophilic group may be chosen, for example, from compounds that are sparingly soluble, very sparingly soluble or even practically insoluble in water at room temperature (15-25° C.). A "sparingly soluble water-soluble compound" is intended to mean that a volume of 100-1000 ml of water is usually required to dissolve 1 gram of said compound. In the case of a "very sparingly soluble water-soluble compound", this volume of water exceeds 1000 ml and can reach up to 10,000 ml. In the case of a "substantially water-insoluble compound", this volume of water exceeds 10,000 ml. In this respect, reference is made to the definitions given in [Figures 1, 2, 3] and in particular in the European Pharmacopeia, reference "1.4 Monographs, 07 / 2014: 10,000".
[0104] The substances specified here may generally be active agents or undesirable substances depending on the application selected. For example, the HPβCDs of the present invention may be used to mask malodors, for example in the form of deodorizing aerosols. They may also be used to prolong the effect of flavors in food compositions or to dissolve and / or stabilize active agents.
[0105] "Active agent" is generally understood to mean any substance of interest, for example a pharmaceutical, veterinary, food, dietary supplement, cosmetic or agrochemical. Examples of such active agents include active pharmaceutical ingredients, colorants, fragrances. Preferably, the active agent of the present invention is an active pharmaceutical ingredient, preferably intended for human use.
[0106] The active agents, particularly active pharmaceutical ingredients, useful for the present invention may be "biological" active agents as well as chemical molecules, as in the case of active ingredients based on or derived from proteins, nucleic acids, such as DNA or RNA, cells, or viruses. Examples of preferred active agents in the present invention include therapeutically active proteins, such as antibodies or hormones.
[0107] A subject of the present invention is also a composition comprising the HPβCD according to the invention and at least one other substance.
[0108] Preferably, said other substance is as defined above in the section on the use of HPβCD according to the invention, e.g. it is an active agent, preferably an active pharmaceutical ingredient, and / or a lipophilic compound or a compound having at least one lipophilic group and / or a compound which is sparingly soluble, very sparingly soluble or even practically insoluble in water at room temperature (15-25° C.).
[0109] These other substances may also be selected from compounds commonly used depending on the use and / or the galenic form desired, provided that the latter are not contrary to the properties desired according to the invention. These other substances may, for example, be selected from binders, (super)disintegrants and lubricants.
[0110] The HPβCD according to the invention and compositions containing them may be in any galenic form deemed suitable by the person skilled in the art, in particular depending on the intended use. They may, for example, be in liquid, solid or semi-liquid form. They may, for example, be solutions, in particular solutions for injection, suspensions, dispersions, emulsions, pellets, granules, films, powders, gels, creams, ointments, pastes, sticks, tablets, hard capsules, soft capsules, osmotic devices, patches.
[0111] In the present invention, when reference is made to the concentration of a substance in a solution expressed as a percentage, and unless otherwise indicated, it is recalled that the latter usually corresponds to the amount in grams of dry substance per 100 ml of solution.
[0112] When reference is made to the dry mass ("dry weight") of a substance, it is of course remembered that this is the mass of the anhydrous substance, in other words, this mass excludes any moisture present in the starting material in powder form.
[0113] The present invention will be more clearly understood from the following examples, which are intended to be illustrative and non-limiting. EXAMPLES
[0114] A. Methods Used to Characterize HPβCD 1. Moisture content (loss of mass on drying) was determined according to the method of USP41 NF36 ("Monograph of Hydroxypropyl Betadex; Loss on Drying") reproduced in the appendix. 2. The reducing sugar content was determined by the Bertrand method, by precipitation of cuprous oxide in a reducing medium, filtration on sintered glass and weighing the residue. 3. The pH of the solutions was determined by measuring the potential difference between two immersed electrodes at 20–25° C. The HPβCD solution consisted of 2 g (dry) HPβCD, 98 g distilled water with resistivity greater than 500,000 Ω·cm, and 0.3 ml of a 225 g / L potassium chloride solution. 4. Chloride (Cl - ) content was determined by potentiometric titration of HPβCD solutions with silver nitrate solutions of known concentrations. 5. The maximum absorbance from 230 to 400 nm was determined based on a distilled water solution containing 2.50 g (dry) HPβCD per 100 ml of solution using a cell with an optical path length of 10 mm. 6. The content of related substances in HPβCD (β-CD, propylene glycol, and other related impurities (including dipropylene glycol)) was determined according to the method conforming to USP41 NF36 ("Monograph of Hydroxypropyl Betadex; Limits of Betadex, Propylene Glycol, and Other Related Substances"). 7. The conductivity was measured at 25°C on a 100 ml solution containing 10% HPβCD prepared in distilled water with a resistivity of more than 500,000 Ω·cm, according to the procedure described in USP41 NF36 ("Monograph of Hydroxypropyl Betadex; Conductivity") reproduced in the appendix. The resistivity R of the so obtained solution was determined by means of an electronic conductivity meter and the conductivity was calculated from the latter (1 / R). 8. The average molar substitution (MS) was determined by NMR according to the method "Monograph of Hydroxypropyl Betadex; Molar Substitution" of USP41 NF36 reproduced in the appendix. 9. The substitution profile was determined by electrospray ionization-mass spectrometry (ESI-MS). A solution of 1 g (dry) / L of HPβCD was prepared in a methanol / water mixture (50 / 50, v / v) with 1 mM sodium acetate. Injections of each sample were performed for 1 min at 10 μl / min and MS data were recorded as follows: Between two successive injections, 500 μl of a methanol / water mixture (50 / 50, v / v) was injected to clean the ion source. Electrospray ionization (ESI) parameters were as follows: spray voltage: 5 kV; nebulizer gas: 9, auxiliary gas: 2; sweep gas: 0; capillary voltage: 23 V; capillary temperature: 275 °C; tube lens: 80 V. Mass spectrometric parameters were: full scan; scan range: 50-200 m / z; mass range: normal, scan speed: improved; acquisition time: 1 min. For each substituted HPβCD molecule (designated HPX, where X is the number of substitutions per β-CD molecule), the extracted ion current (XIC) for each ion was integrated and compared to the sum of all HPX ion currents, where the intensity of the corresponding peak was greater than that of the background noise. Since the sodium adducts were the most intense HPβCD ions, the area under the curve of the peak corresponding to each HPX was integrated and related to the sum of the areas of the HPX ions considered for characterization (intensity greater than that of the background noise) and expressed as a percentage. 10. The content of organic solvents was determined by gas chromatography with mass spectrometric detection (GC / MS). More precisely, the analysis was carried out by headspace GC / MS. The operating conditions were as follows: Bruker GC / MS equipped with a Vf-wax column of 30m*0.25mm, df0.25μm; temperature program: 5 min at 40°C, 5°C / min to 230°C; injector 250°C split ratio 1:10; EI + MS detector at 1000 Hz. Samples were prepared as follows: 0.2 g of dry HPβCD was dissolved in 1 ml of ultrapure water. 11. Substitution patterns were determined according to the “box-keeper” method discussed above.
[0115] B. Prior Art: MS and β-CD Content Values of Commercially Available HPβCD In this section, MS and β-CD content values were measured for various commercial HPβCDs (Meas.). Supplier details, when available, are also provided for information (Spec.).
[0116] [Table 1]
[0117] These results confirm that the commercially available HPβCD is not consistent with low MS and low residual β-CD content. Thus, for example, KLEPTOSE® HP, CAVASOL® W7 HP7 and COMPLEXOL-HP products have a β-CD content of 0.3% or less, but systematically have an MS of more than 0.71. Conversely, KLEPTOSE® HPB, CAVASOL® W7 HP, CAVASOL® W7 HP5 and C*CAVITRON® products have an MS of less than 0.71, but their residual β-CD content is systematically more than 0.3%.
[0118] C. Preparation and Characterization of Inventive and Non-Inventive HPβCD (MS and βCD) 1. Method 1 - involves decolorization, filtration and purification by membrane purification The aim of this section is to present the influence of the hydroxypropylation parameters on the properties of the resulting HPβCD.
[0119] The HPβCD (IN-1) of the invention was prepared as follows: 1313 g of commercial β-cyclodextrin (β-CD) (corresponding to 1188 g of anhydrous β-CD) were dissolved in an alkaline medium with stirring in an autoclave under an inert atmosphere. A solution was thus obtained containing 52% of β-CD by dry weight relative to the total weight of the solution and 2.9% of sodium hydroxide ([NaOH] in the table below) relative to the dry weight of β-CD. The reaction medium was maintained at a temperature [T] of 95° C. for 30 minutes, then 361.6 g of propylene oxide were added at a rate [D] of 0.22 kg / h / kg of dry β-CD, i.e. a propylene oxide / anhydrous glucose [PO / G] molar ratio of 0.85 / 1.00. After the end of the introduction of propylene oxide, the reaction medium was kept under stirring for 4 hours and then neutralized with hydrochloric acid.
[0120] The HPβCD was then purified and dried in aqueous medium, i.e. without organic solvents, by the following technique: - bleaching; - Filtration; - Membrane purification; - Evaporative drying
[0121] The activated carbon decolorization step was carried out in batch mode with stirring at 70°C ± 5°C for a minimum of 1 hour. The medium was then filtered through a cricket filter and then through a 0.22 μm cartridge filter. The membrane purification step was carried out using a nanofiltration module equipped with a membrane with a cut-off threshold of 800 Da, specifically at a pressure below 35 bar and a temperature above 45°C. The propylene glycol content of the retentate was monitored by HPLC assay. The operation was stopped as soon as the propylene glycol content on the dry product reached less than 0.5% by weight. The HPβCD so obtained was then dried under reduced pressure in a rotary evaporator to have a solids content of more than 95% by weight.
[0122] Comparative HPβCD (CP-1) was prepared as follows: 656 g of commercial β-cyclodextrin (β-CD) (corresponding to 594.4 g of anhydrous β-CD) were dissolved in an alkaline medium with stirring in an autoclave under an inert atmosphere. A solution was thus obtained containing 52% of β-CD by dry weight relative to the total weight of the solution and 2.9% of sodium hydroxide relative to the dry weight of β-CD. The reaction medium was maintained at a temperature [T] of 75 °C for 30 minutes, then 182.6 g of propylene oxide were added at a rate [D] of 0.14 kg / h / kg of dry β-CD, i.e. a propylene oxide / anhydrous glucose [PO / G] molar ratio of 0.86 / 1.00. After the end of the introduction of propylene oxide, the reaction medium was kept under stirring for 4 hours and then neutralized with hydrochloric acid. The HPβCD so obtained was purified and dried in a manner similar to that of HPβCD IN-1.
[0123] The obtained HPβCD were characterized with respect to their MS and their β-CD content. The hydroxypropylation conditions and further the values of MS and β-CD content are given in the table below.
[0124] [Table 2]
[0125] Next, another test was performed as follows: In each test, the amount of anhydrous β-CD used was about 250 g, the amount of water introduced and the amount of propylene oxide corresponding proportionally to the amounts used in the preparation of HPβCD IN-1. In particular, this means that the [PO / G] molar ratio was equal to 0.85 / 1.00. The temperature [T] of the reaction medium before the introduction of propylene oxide was 110° C. The various amounts of sodium hydroxide [NaOH] tested are given in the table below as a dry percentage of sodium hydroxide relative to the dry weight of β-CD. Propylene oxide was added at a rate [D]. After the reaction, the reaction medium was neutralized with hydrochloric acid. For each sodium hydroxide [NaOH] content tested, two crude reaction products were produced, which were then combined in order to have enough material for the nanofiltration step of purification. The HPβCD crude reaction products thus obtained were: It was purified and dried in the same manner as for HPβCD IN-1.
[0126] The obtained HPβCD were characterized with respect to their MS and their β-CD content. The hydroxypropylation conditions and further the values of MS and β-CD content are given in the table below.
[0127] [Table 3]
[0128] All these tests show that if the hydroxypropylation conditions are properly designed, it is possible to obtain HPβCD with MS and β-CD contents as targeted by the present invention.
[0129] A great advantage of the purification is that it is not necessary to include organic solvents, and therefore the HPβCD of the present invention may be free of organic material other than that which would normally result from the hydroxypropylation step and the raw materials used in said hydroxypropylation.
[0130] 2. Method 2 - With decolorization and additional filtration The purpose of this section is to present the optimization process for the preparation of HPβCD of the present invention.
[0131] The HPβCD according to the invention (IN-2) was prepared as follows: 1305 g of commercial β-cyclodextrin (β-CD) (corresponding to 1204 g of anhydrous β-CD) were dissolved in alkaline medium with stirring in an autoclave under an inert atmosphere. A solution was obtained containing 52% β-CD by dry weight relative to the total weight of the solution and 2.9% sodium hydroxide relative to the dry weight of β-CD. The reaction medium was maintained at a temperature [T] of 95° C. for 30 minutes, then 367 g of propylene oxide were added at a rate [D] of 0.22 kg / h / kg of dry β-CD, i.e. a propylene oxide / anhydroglucose [PO / G] molar ratio of 0.85 / 1.00. After the end of the introduction of propylene oxide, the reaction medium was kept under stirring for 4 hours and then neutralized with hydrochloric acid.
[0132] The obtained HPβCD was then purified and dried in aqueous medium, i.e. without the use of organic solvents, by undergoing the following steps: - bleaching; - Filtration; - Membrane purification; - Demineralization; - bleaching; - Filtration; - spray drying
[0133] The decolorization step was carried out by activated carbon treatment at 70 °C for 1 h. The medium was then filtered through a bag filter, then a 1 μm, and then a 0.22 μm cartridge filter. The membrane purification step was carried out with a nanofiltration module equipped with a membrane with a cut-off threshold of less than 800 Da, at a pressure less than 35 bar and a temperature greater than 45 °C. The propanediol glycol content of the retentate was monitored by HPLC assay. The nanofiltration operation was stopped immediately after the propanediol content in relation to the dry product reached less than 0.1 wt%. The demineralization step was carried out by passing the mixture through, inter alia, cationic and then anionic ion exchange columns and finally through a mixed bed in order to obtain an outlet resistivity greater than 500,000 Ω·cm. The second decolorization step was carried out in batch mode by activated carbon treatment with stirring at 70 °C for at least 1 h. The HPβCD solution was then filtered through a bag filter, then a 1 μm, and then a 0.22 μm cartridge filter. The HPβCD solution was then spray dried to obtain HPβCD in powder form.
[0134] Next, a thorough characterization of the HPβCD IN-2 of the present invention was carried out. The results are shown in the table below:
[0135] [Table 4]
[0136] D. Substitution Patterns of Inventive and Non-Inventive HPβCD In this section, the inventors determine the substitution pattern of the HPβCD of the present invention, the substitution pattern of comparative HPβCDs, and also the substitution pattern of commercially available HPβCD. In the case of HPβCD IN-2, several batches were tested.
[0137] The results, expressed as percentages, are shown in Tables 5 and 6. MS and residual β-CD values are also reported. "Mono": the percentage of substitutions corresponding to one substitution (2OHP, 3OHP, 6OHP); "Di": the percentage of substitutions corresponding to two substitutions (2,3-di-OHP, 2,6-di-OHP, 3,3'-di-OHP); "Tri": percentage of substitution corresponding to tri-substitution (2,3,6-tri-OHP); "C2 / C6": C2 / C6 substitution ((2OHP + 2,3-di-OHP + 2,6-di-OH The ratio of (6OHP+2,6-di-OHP+2,3,6-tri-OHP) / (6OHP+2,6-di-OHP+2,3,6-tri-OHP)); "C2 / C3": the ratio of C2 / C3 substitutions ((2OHP+2,3-di-OHP+2,6-di-OHP+2,3,6-tri-OHP) / (3OHP+2,3-di-OHP+3,3'-di-OHP+2,3,6-tri-OHP)
[0138] [Table 5]
[0139] [Table 6]
[0140] NOTE: For all HPβCDs tested, no signals corresponding to other types of substitution were obtained (e.g., in the case of the 3,6-di-OHP type). Thus, no detectable amounts were obtained for anhydroglucose units with types of substitution other than those shown in Tables 5 and 6.
[0141] These results show that the HPβCD of the present invention has a specific substitution pattern, especially compared to the CAVASOL® W7 HP Pharma, CAVITRON® W7 HP5 Pharma and CAVITRON® W7 HP7 Pharma products, which were also analyzed.
[0142] According to experiments carried out by the inventors (data not presented here), substitution patterns such as those of the HPβCD of the present invention appear to result in certain properties, in particular improved efficiency in the stabilization of substances, in particular active pharmaceutical ingredients, more particularly biologically active agents such as pharma- ceutical active proteins. In particular, for the stabilization of therapeutic proteins, a significant reduction in protein aggregation was obtained with HPβCD having a substitution pattern such as that of the HPβCD of the present invention compared to that obtained with the CAVASOL® W7 HP Pharma, CAVITRON® W7 HP5 Pharma and CAVITRON® W7 HP7 Pharma products.
Claims
[Claim 1] (a) preparing an aqueous solution comprising β-cyclodextrin (β-CD) and sodium hydroxide, wherein the amount of sodium hydroxide used is less than 3.7% by dry weight of sodium hydroxide relative to the dry weight of β-CD; In step (b) of adding propylene oxide to the aqueous solution obtained in step (a), the temperature of the aqueous solution obtained in step (a) before the introduction of the propylene oxide is selected in the range from 80° C. to 120° C.; the propylene oxide / anhydroglucose molar ratio used is chosen within the range of 0.70 / 1.00 to 0.86 / 1.00; - the addition rate of propylene oxide is selected in the range of 0.15 to 0.30 kg / h / kg of β-CD; and step (b) comprising: a purification step (c), characterized in that no organic solvent is used; (d) recovering the hydroxypropyl-β-cyclodextrin thus obtained; 1. A method for preparing hydroxypropyl-β-cyclodextrin, comprising:
Citation Information
Patent Citations
Method for preparing hydroxypropyl-beta-cyclodextrin
CN102040675A
Preparation method of hydroxypropyl-beta-cyclodextrin
CN102558394A
Green preparation method of hydroxypropyl cyclodextrins
CN108034010A
The water solubility of the drug-containing pharmaceutical preparations or slightly unstable and its manufacturing method
JP1986500788A
Powdered hydroxypropyl-β-cyclodextrin composition and method for producing same
JP1998504351A
